U.S. stock index futures on Tuesday were lower, with market participants receiving a barrage of quarterly reports from major ...

Pfizer ( PFE) reported mixed first quarter earnings Tuesday, as the company struggles to gain investor interest in its ...

NEW YORK, April 26, 2025--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination ...

Analysts expect the New York-based company to report quarterly earnings at 68 cents per share, down from 82 cents per share ...

As April gives way to May, the market braces for a blockbuster week packed with earnings from some of the biggest names ...

Reviewing PFE’s five-year history, the stock has experienced a balanced 50-50 distribution of positive and negative returns ...

Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their ...

Pfizer, however, reaffirmed its full-year forecast and announced measures to mitigate the impact of potential tariffs on ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President Donald Trump’s trade ...

(PFE) on Tuesday reported first-quarter profit of $2.97 billion. On a per-share basis, the New York-based company said it had profit of 52 cents.